David Dominguez-Sola, MD, PhD
img_David Dominguez-Sola
ASSOCIATE PROFESSOR | Oncological Sciences
ASSOCIATE PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics
B Cells, Cancer, Cell Biology, DNA Replication, Gene Regulation, Immunology, Lymphocytes, Lymphoma, Molecular Biology, Transcription Factors, Transgenic Mice, Tumorigenesis
Multi-Disciplinary Training Area
Cancer Biology [CAB], Immunology [IMM]
Oncogenes and Early B cell Lymphomagenesis

Invisible to the human eye, cancer initiation is believed to shape the molecular and cellular landscape of all cancers. Although we have been able to probe these pre-malignant stages in a handful of tumor types, our knowledge remains exceptionally limited for other malignancies like B-cell lymphomas.

B cell lymphomas occur both in adult and children, being one of the most common cancers in the latter group. Notably, an importantfraction of lymphomas rely on the activation of oncogenes through particular genetic rearrangements (e.g. translocations). These genetic events are known to drive lymphomagenesis in animal models, and constitute a useful system to study the basic mechanisms of cancer initiation and progression.


Most human B-cell lymphomas arise from B-lymphocytes (B cells) recruited to transient microanatomic structures known as Germinal Centers. Germinal centers are highly organized and dynamic compartments where B cells are trained and selected for their ability to efficiently recognize antigens, a process that is essential to sustain efficient immune responses. However, the molecular and cellular events driving the germinal center also impose a high risk for cellular transformation and lymphomagenesis.


Our laboratory is particularly interested in understanding the early steps of B cell lymphomagenesis, and in deciphering how the tissue and cellular contexts affect how oncogenes drive lymphoma initiation and shape the genetic landscape of lymphoma cells, with a particular interest in B-cell lymphomas driven by deregulation of the c-Myc protooncogene. To address these questions we use a multiplicity of in vitro and in vivo methodologies that combine strategies borrowed from both the cancer biology and immunology fields. Using this approach we are refining our knowledge on the cellular origin of B-cell lymphomas and the basic mechanisms of cancer initiation.

Visit the Dominguez-Sola Laboratory

MD, Autonomous University of Barcelona (UAB) Medical School

PhD, Pompeu Fabra University (UPF)

Columbia University

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Dominguez-Sola did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.